Jena, August 30, 2010 — Analytik Jena AG is now represented in the Life Science growth segment on the Austrian and Hungarian markets. With its new sales partner Bartelt Labor- und Datentechnik, both countries will be henceforth developed as sales regions in the field of molecular diagnostics. The dealer agreement on Analytik Jena and Biometra products was concluded for the upcoming 2010/2011 financial year with a sales target of EUR 150 thousand. Shortly after the agreement was signed, first orders were taken.

"With Bartelt, the field of Life Science is now also well positioned in neighboring Austria and Hungary," said Klaus Berka, CEO of Analytik Jena AG. "The strong, international dealer network that we have bundled together under the aegis of Analytik Jena is an essential cornerstone of our success in our core business. In doing so, we combine the Group’s broad portfolio and our sales partner’s proximity to customers. In developing a broad dealer structure, we want to establish this success model in the Life Science segment too."

Bartelt is an independent family-run company headquartered in Graz, with sales offices in Vienna, Linz, Innsbruck and Budapest. In the five business units of Laboratory Technology, Chemicals, Service, Glassblowing, Process Technology and Data Processing, the sales partner covers virtually all requirements that modern laboratories and laboratory-related fields have from their partners.

Analytik Jena generated sales of EUR 20.3 m in the Life Science field after nine months, thus continuing its positive development.

Jena, August 19, 2010 — Analytik Jena AG has won two orders for the delivery to China of 20 atom absorption spectrometry devices.

A total of nine ZEEnit 700 devices are to be deployed as part of a project for the quality control of agricultural products under the aegis of the Jilin Academy of Agricultural Sciences. Jilin is a province in North East China known for its heavy industry and agriculture.
Another order for 11 contrAA^® 700 devices has been placed by the China National Materials Group Corporation (SINOMA), a state-managed enterprise that is one of China's leading groups in the non-metalworking sector.

"In the area of atom absorption spectrometry, Analytik Jena is one of the world's technological leaders with decades of experience in spectrometer development," said Klaus Berka, CEO of Analytik Jena AG. "What is especially interesting is that contrAA^® is the first representative of a new generation of systems for AAS with a degree of innovation that to date remains unsurpassed. This gives us an important competitive advantage in large growth markets such as China, where we are one of the largest importers in this segment."

In the previous financial year 2008/2009, Analytik Jena generated sales of approximately EUR 10.0 m, making the People's Republic one of the company's largest export markets.

• Sales within range of forecasts with 10.2 % increase
  
• Operating earnings below expectations
  
• Dividend payment remains goal for the financial year

Jena, August 12, 2010 — With sales of EUR 59.6 m, Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) has achieved an important milestone towards being able to close the current financial year with record sales once again. This was announced today by the analytical measuring technology manufacturer at the presentation of its nine-month figures.

Sales and earnings

Analytik Jena generated consolidated sales of EUR 59.6 m (previous year EUR 54.1 m) in the first nine months of financial year 2009/2010, equivalent to a year-on-year increase of 10.2 %. Operating earnings (EBIT) amount to EUR 3.2 m (previous year EUR 4.9 m), a decline of 33.5 % as against the previous year. The EBIT margin decreased significantly in the reporting period, ending it at 5.4 % (previous year 9.0 %). Analytik Jena posted a net profit of EUR 2.5 m, corresponding to earnings per share of EUR 0.47 (previous year EUR 0.55).

"With its nine-month figures, the Company is continuing its overall successful business development. In addition to new record sales, we also want to exceed the previous year in terms of earnings per share", said Klaus Berka, Chairman of the Executive Board of Analytik Jena AG. "The causes of our below-expectations result after nine months, and of the adjusted key figures for the year 2009/2010 as a whole, are mainly temporary effects which occurred across all business units", continued Berka.

According to the Company, this is attributable to the persistent disappointing sales in the Optics segment, where the anticipated recovery has not yet occurred. Operating earnings also include one-off costs arising from combination of the two subsidiaries Analytik Jena Japan Co. Ltd. and CyBio Japan Co. Ltd., which is being liquidated, in the amount of approximately EUR 0.3 m. Write-downs totaling around EUR 0.6 m in relation to the purchase price allocation as part of the acquisition of Biometra and CyBio must also be taken into account. The EUR 1.2 m decrease in sales in Analytical Instrumentation as against the previous year also reduced operating earnings.

In the core business of Analytical Instrumentation, Analytik Jena again saw a stable sales development, generating sales of EUR 35.9 m (previous year EUR 37.1 m). However, the Company is still below its figures for the previous year. As at the end of June, Analytik Jena managed to exceed the previous year’s level of incoming orders in Analytical Instrumentation for the first time in the financial year. In view of the two major orders gained in the prior-year period with a volume of approximately EUR 3.5 m, this can be considered an excellent development. In the current fourth quarter, the Company expects to be able to slightly exceed the previous year’s annual sales in this division.

The growth segment of Life Science also continued its positive sales development with strong growth rates. Here the Group generated sales of EUR 20.3 m (previous year EUR 12.1 m) after nine months, equivalent to a 67.5 % increase. It should be noted that the subsidiaries Biometra GmbH and CyBio AG were not yet fully consolidated in the equivalent period of the previous year. Overall, this division is currently still going through a phase dominated by research and development as well as structuring of sales.

In the Optics division, Analytik Jena posted profitable sales of EUR 3.4 m (previous year EUR 4.9 m) in the reporting period, 29.9 % lower than in the previous year.

Balance sheet and cash flow

The Group’s total assets rose as of the reporting date June 30, 2010, amounting to EUR 79.7 m as compared to EUR 75.5 m as of September 30, 2009. Equity increased to EUR 40.2 m (September 30, 2009: EUR 38.4 m), equal to an equity ratio of 50.4 %. The Group’s cash and cash equivalents amounted to EUR 7.2 m as of the end of the reporting period, compared to EUR 10.4 m as of September 30, 2009.

Outlook

For financial year 2009/2010, the Analytik Jena Group anticipates earnings before interest and taxes (EBIT) of around EUR 5.0 m and earnings per share (EPS) of approximately EUR 0.60 with revenue amounting to roughly EUR 80.0 m. In the fourth quarter, Analytik Jena will focus on improving earnings on the basis of comparatively higher sales. In Analytical Instrumentation, the Company expects the current remaining decline in sales to be cancelled out or exceeded. In the coming quarter, the challenge in the high-growth Life Science segment will be to continue the establishment of sales structures in the two key markets of Japan and China, which was initiated at the start of the year, in order to generate significant sales in the coming financial year. In the Optics division, a slight recovery of the market is anticipated towards the end of the year following a very weak start into the financial year. This recovery is also expected to be reflected in increasing sales.

"We expect our growth path to be continued in our operating business, after the current stabilization phase and we anticipate that we will be able to close financial year 2009/2010 successfully and with record sales despite slightly adjusted results", emphasizes Berka.

The detailed financial report is available at
http://berichte.analytik-jena.de/9-MonthReport_0910.pdf

Jena, July 28, 2010 — Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) today announced its preliminary sales and earnings figures for the first nine months of the current 2009/2010 financial year. The Thuringia-based provider of analytical instrumentation technology generated an operating result (EBIT) of EUR 3.2 m on the back of sales of EUR 59.6 m. Earnings per share amounted to EUR 0.47.

Based on the current course of business, the Company expects to record EBIT of around EUR 5.0 m and earnings per share of around EUR 0.60 for the financial year as a whole, down on its initial forecasts.

This adjustment is due to the sustained difficult development in the Optics segment, which has not enjoyed the recovery that was expected. The Company also reported non-recurring effects from the closure of CyBio Japan in the past quarter, as well as a sharp increase in costs for the establishment of a uniform international sales structure in the Life Science sector.

The Company still expects to achieve record sales of around EUR 80.0 m and intends to recommend the distribution of a dividend to the Supervisory Board at its meeting in December 2010 to adopt the annual financial statements.

This information is based on preliminary key financial figures. The complete figures for the first nine months of the 2009/2010 financial year will be announced on August 12, 2010.

Contact:
Dana Schmidt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Phone: +49 (0) 36 41  77-92 81
E-mail: ir@analytik-jena.com

Jena, June 30, 2010 — Analytik Jena AG has received an extensive new order from Poland. The system provider of analytic measurement technology headquartered in Jena, Germany, is delivering a total of 20 TOC analyzers to the Polish Inspectorate of Environmental Protection (GIOS) as well as their regional investigations offices. The company was therefore able to further strengthen its market position in the neighboring country.

The project was acquired by marketing partner Meranco in Poznan, Poland, which has successfully been acting as an exclusive distributor for the business unit of Analytical Instrumentation in this region for many years.

"This project is a great success for Analytik Jena. We are able to further expand our position as a provider of high-quality analytic measurement instruments in Poland and secure important competitive advantages," said Klaus Berka, CEO of Analytik Jena AG.

The TOC analyzer is an instrument for measuring the total organic carbon content in aqueous and solid samples. The technology is used for determining the water quality in lakes, rivers and waste waters. The area of environmental analysis is a globally growing market determined by international and national regulations. The analysis of total organic carbon (TOC) is an important parameter in this process.

"With increasing general conditions in the area of environmental protection and the related area of resource management, the requirements on appropriate technology for analysis of this sector are increasing as well. This project clearly shows that the products of Analytik Jena are recognized as excellent technologies, particularly in the public authority segment abroad," said Torsten Olschewski, Sales and Marketing Director in the Analytical Instrumentation business unit at Analytik Jena.

The project is part of the program for the regional development of Poland, co-financed by the European Union. The goal is to optimize the handling of existing resources and to avert environmental risks.

Jena, June 21, 2010 – With the integration of the sales unit of CyBio Japan Co. into Analytik Jena AG's Japanese subsidiary, the Jena-based systems provider for analytical instrumentation technology is bundling its sales competence in one of the biggest and most dynamic markets in this segment. At the dealer conference organized by Analytik Jena in Yokohama, Japan, on May 28, 2010, the company launched the joint Group-wide market campaign.

"Our goal is to further expand Analytik Jena's international network and to exploit the experience and structures of the successful Analytical Instrumentation division for other business units and subsidiaries too", said Klaus Berka, CEO of Analytik Jena AG. "Thanks to the extensive synergies resulting from bundling sales structures and expertise in the Group, we will be able to achieve significant sales and growth potential."

With an export ratio of nearly 70% and a distinctive international retailer network, Analytik Jena now operates in more than 90 countries worldwide. In the past fiscal year, the Group generated sales of close to EUR 50 million outside Germany.

"The Japanese market for analytical instrumentation technology is the third biggest in the world and will develop rapidly. Many governments in the Far East have invested considerable sums in biological and pharmaceutical research and established related programs", stressed Torsten Olschewski, head of sales and marketing in the Analytical Instrumentation division at Analytik Jena. "In the atomic spectroscopy and elemental analysis product lines, we will position ourselves even more broadly with additional products and will benefit in particular from our good reputation in Asia."

A total of 62 Japanese retailers participated in the conference in Yokohama. The event focused on the development and consolidation of the Life Science division and in particular on the integration of CyBio, which caters to a specific industry with the major pharmaceutical groups, into the existing sales activities.

"The pharmaceuticals market has been undergoing a dramatic change in recent years. Now we must push forward CyBio's international business with high-quality, innovative products and the right market strategy", said Berka.

Photos are available at
http://www.analytik-jena.com/en/site/Press-Center/Downloads__3885/